PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27912843-5	2016	Strategies aiming to increase cytosolic citrate should be developed and tested in humans, knowing that experimental studies have shown that administration of citrate and/or inhibition of ACLY arrest tumor growth, inhibit the expression of the key anti-apoptotic factor Mcl-1, reverse cell dedifferentiation and increase sensibility to cisplatin.	Citric Acid	158-165	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	269-274	
24103422-0	2013	Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells.	Citric Acid	34-41	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	14-19	
24103422-2	2013	We have studied their concomitant inhibition, using ABT 737 or siRNA targeting XL1 and citrate, a molecule which reduces the expression level of Mcl-1.Two cisplatin-chemoresistant ovarian cell lines (SKOV3 and IGROV1-R10) were exposed to ABT 737 or siRNA targeting XL1 and citrate at various individual concentrations, or combined.	Citric Acid	87-94	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	145-150	
24103422-4	2013	Western blot analyses were performed to detect various proteins implied in apoptotic cell death pathways.Mcl-1 expression was barely reduced when cells were exposed to citrate alone, whereas a mild reduction was observed after ABT 737 treatment.	Citric Acid	168-175	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	105-110	
24103422-5	2013	Concomitant inhibition of Bcl-xL and Mcl-1 using ABT 737 or siXL1 associated with citrate was far more effective in inhibiting cell proliferation and inducing cell death than treatment alone.Given that few, if any, specific inhibitors of Mcl-1 are currently available, anti-glycolytic agents such as citrate could be tested in association with synthetic inhibitors of Bcl-xL.	Citric Acid	82-89	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	37-42	
24103422-5	2013	Concomitant inhibition of Bcl-xL and Mcl-1 using ABT 737 or siXL1 associated with citrate was far more effective in inhibiting cell proliferation and inducing cell death than treatment alone.Given that few, if any, specific inhibitors of Mcl-1 are currently available, anti-glycolytic agents such as citrate could be tested in association with synthetic inhibitors of Bcl-xL.	Citric Acid	82-89	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	238-243	
24103422-5	2013	Concomitant inhibition of Bcl-xL and Mcl-1 using ABT 737 or siXL1 associated with citrate was far more effective in inhibiting cell proliferation and inducing cell death than treatment alone.Given that few, if any, specific inhibitors of Mcl-1 are currently available, anti-glycolytic agents such as citrate could be tested in association with synthetic inhibitors of Bcl-xL.	Citric Acid	300-307	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	37-42	
21498699-7	2011	RESULTS: A 3-day continuous exposure to citrate led to near destruction of the cell population in both cell lines, apoptotic cell death occurred through the mitochondrial pathway in a dose- and time-dependent manner, associated with the reduction of the anti-apoptotic Mcl-1 protein in both lines.	Citric Acid	40-47	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	269-274	
21498699-8	2011	CONCLUSION: Citrate demonstrates strong cytotoxic activity against two gastric cancer lines, leading to an early diminution of expression of Mcl-1 and to massive apoptotic cell death involving the mitochondrial pathway.	Citric Acid	12-19	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	141-146	
19414371-3	2009	RESULTS: A 3-day continuous exposure to citrate led to apoptotic cell death via a mitochondrial pathway, associated with a reduction of anti-apoptotic protein Bcl-x(L) and Mcl-1 expression.	Citric Acid	40-47	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	172-177	
35626081-11	2022	Consistently, in various cultured cancer cells (including melanoma, sarcoma, hematologic, and epithelial cancer cells), this "citrate strategy" efficiently inhibits the IGFR1/AKT pathway, promotes PTEN activity, reduces Bcl-xL and MCL1 expression, and increases sensitivity to standard chemotherapy.	Citric Acid	126-133	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	231-235